Assessment of the safety of nicotinamide mononucleotide (NMN) in healthy subjects; phase I study. The clinical trial to evaluate metabolic-syndrome-related parameters to develop NMN as Foods with Function Claims.

Assessment of the safety of nicotinamide mononucleotide (NMN) in healthy subjects; phase I study. The clinical trial to evaluate metabolic-syndrome-related parameters to develop NMN as Foods with Function Claims. - Assessment of the safety of nicotinamide mononucleotide (NMN).

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021309

Enrollment

Registered

2016-03-03

Start date

2016-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

the single intake of NMN.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: the healthy subjects who agree to the study.

Exclusion criteria

Exclusion criteria: 1 the subjects with a previous history of diseases. 2 the subjects with malignant neoplasms. 3 the subjects with serious infections. 4 the subjects with psychiatric disorders. 5 the subjects with ophthalmic disorder. 6 the subjects with allergic disorders. 7 the subjects who are regarded as inadequate by the investigator.

Design outcomes

Primary

Measure	Time frame
the safety of NMN (physical and laboratory examinations).	—

Secondary

Measure	Time frame
the kinetics of NMN.	—

Countries

Japan

Contacts

Public ContactJunichiro Irie

Keio University School of Medicine Division of Endocrinology, Metabolism and Nephrology

j-irie@z8.keio.jp03-5363-3797

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026